Update on criteria for cadaveric donor selection for liver transplantation;Mise au point sur les critères de sélection des donneurs cadavériques pour la transplantation du foie

Gastroenterologie Clinique et Biologique

Volumn 27, Issue 2, 2003, Pages 163-175

  Yandza, Thierry ^a   Aubert, Frédéric ^b   Fourcade, Laurent ^a   Jan, Dominique ^a   Lacaille, Florence ^a   Hubert, Philippe ^a   Revillon, Yann ^a  

^a HÔPITAL NECKER ENFANTS MALADES   (France)

^b ARMAND TROUSSEAU HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ANEURYSM RUPTURE; BACTERIAL INFECTION; BLOOD GROUP ABO INCOMPATIBILITY; BRAIN ARTERY ANEURYSM; BRAIN HYPOXIA; CADAVER DONOR; CREUTZFELDT JAKOB DISEASE; FATTY LIVER; HEMODYNAMICS; HOSPITALIZATION; HUMAN; HYPERNATREMIA; INTOXICATION; LIVER FUNCTION TEST; LIVER TRANSPLANTATION; REVIEW; REYE SYNDROME; SCREENING TEST; SEROLOGY;

AGE FACTORS; BODY WEIGHT; CADAVER; CAUSE OF DEATH; FATTY LIVER; HEMODYNAMIC PROCESSES; HUMANS; LIVER DISEASES; LIVER TRANSPLANTATION; TISSUE AND ORGAN PROCUREMENT; TISSUE DONORS; VIRUS DISEASES;

EID: 0037300584     PISSN: 03998320     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (152)

1. Alexander JW. Donor management and procurement, Curr Opin Organ Transplant 2000;5:225-6.
2. Etablissement des Greffes. Rapport d'activité et bilan des activités de prélèvement et de greffe en France, 1999.
3. Hauptman PJ, O'Connor KJ. Procurement and allocation of solid organs for transplantation. N Engl J Med 1997;336:422-31.
4. FDA guidance for industry and/or for FDA reviewers/staff and/or compliance: guidance for the preparation of a premarket notification application for processed human dura mater. July 31, 1999.
5. Wachs ME, Ascher NL. Selection of multivisceral cadaveric organ donors. In: Collins M, Dubernard JM, Land W, Persijn (eds). Procurement, preservation and allocation of vascularized organs. Kluwer Academic Publishers, 1997:47-54.
6. Hassanein TI, Gavaler JS, Fishkin D, Gordon R, Starzl TE, Van Thiel DH. Does the presence of a measurable blood alcohol level in a potential organ donor affect the outcome of liver transplantation? Alcohol Clin Exp Res 1991;11:300-3.
7. Kauffman HM, McBride MA, Cherikh WS, Spain PC, Marks WH, Roza AM. Transplant tumor registry: donor related malignancies. Transplantation 2002;74:358-62.
8. Penn I. Donor transmitted disease: cancer. Transplant Proc 1991;23: 2629-31.
9. Kauffman HM, McBride MA, Delmonico FL. First report of the United Network for organ sharing Transplant Tumor Registry: donors with a history of cancer. Transplantation 2000;70:1747.
10. Colquhoun SD, Robert ME, Shaked A, Rosentahl JM, Millis TM, Farmer DG, et al. Transmission of CNS malignancy by organ transplantation. Transplantation 1994;57:970-3.
11. Transplant Newsletter: International figures on organ donation and transplantation activities 1998. In: Recommendations of the Select Committee of Experts on the Organisational Aspects of Cooperation in Organ and Tissue Transplantation, vol 4. Madrid: Aula Medica; 1999.
12. Garcia CE, Bramhall S, Mirza DF. Use of marginal donors. Curr Opin Organ Transplant 2000;5:50-6.
13. Morse JH, Turcotte JG, Merion RM, Campell DA, Burtch GD, Lucey MR. Develepment of a malignant tumor in a liver transplant graft procured from a donor with a cerebral neoplasm. Transplantation 1990;50:875.
14. Jonas S, Beschstein WO, Lemmens HP, Neuhaus R, Thalmann U, Neuhaus P. Liver graft-transmitted glioblastoma multiforme. A case report and experience with 13 multiorgan donors suffering from primary cerebral neoplasia. Transplant Int 1996;9:426-9.
15. Lefrancois N, Touraine JL, Cantarovitch D, Cantarovitch F, Faure JL, Dubernard JM, et al. Transmission of medulloblastoma from cadaver donor to three organ transplant recipients. Transplant Proc 1987;19: 2242.
16. Fecteau AH, Penn I, Hanto DW. Peritoneal metastasis of intracranial glioblastoma via a ventriculoperitoneal shunt preventing organ retrieval: case report and review of the literature. Clin Transplant 1998;12:348.
17. Donovan JA, Simmons FA, Esrason KT, Jamehdor M, Busuttil RW, Novak JM, et al. Donor origin of a posttransplant liver allograft malignancy identified by fluorescence in situ hybridization for the Y chromosome and DNA genotyping. Transplantation 1997;63:80-4.
18. Detry O, Honore P, Jacquet N, Meurisse M. Management of recipients of hepatic allografts harvested from donors with malignancy diagnosed shortly after transplantation. Clin Transplant 1998;12:579-81.
19. Centers for Disease Control. Guidelines for preventing transmission of human immunodeficiency virus through transplantation of human tissue and organs. Morb Mort Wkly Rep 1994;43:1.
20. Delmonico FL, Snydman DR. Organ donor screening for infectious diseases. Transplantation 1998;65:603-10.
21. Dodson SF, Issa S, Araya V, Gayowski T, Pinna A, Eghtesad B, et al. Infectivity of hepatic allografts with antibodies to hepatitis B virus. Transplantation 1997;64:1582-4.
22. Mutimer D. Positive suggestions about the anti-HBc positive donor. Gut 2002;50:7-8.
23. Dickson RC, Everhart JE, Lake JR, Wei Y, Seaberg EC, Wiesner RH, et al. Transmission of hepatitis B by transplantation of livers from donors positive for antibody to hepatitis B core antigen. The National Institute of Diabetes and Digestive and Kidney Diseases Liver Transplantation Database. Gastroenterology 1997;113:1668-74.
24. Gow PJ, Mutimer DJ. De novo hepatitis B infection acquired during liver transplantation. Q J Med 2001;94:271-5.
25. Uemoto S, Sugiyama K, Marusawa H, Inomata Y, Asonuma K, Egawa H, et al. Transmission of hepatitis B virus from hepatitis B core antibody-positive donors in living related liver transplants. Transplantation 1998;65:494-9.
26. Wachs ME, Amend WJ, Ascher NL, Bretan PN, Emond J, Lake JR, et al. The risk of transmission of hepatitis B from HbsAg (-), HbcAb (+), HBIgM (-) organ donors. Transplantation 1995;59:230-40.
27. Kadian M, Hawkins L, Nespral J, Schwartz M, Miller C. Use of hepatitis B core antibody positive multiorgan donors. Presented at the Second International Conference of the Society of Organ Sharing. Vancouver, British Colombia, Canada 1993.
28. Roque-Afonso AM, Feray C, Samuel D, Simoneau D, Roche B, Emile JF, et al. Antibodies to hepatitis B surface antigen prevent viral reactivation in recipients of liver grafts from anti-HBC positive donors. Gut 2002;50:95-9.
29. Yu AS, Vierling JM, Colquhoun SD, Amaout WS, Chan CK, Khanafshar E, et al. Transmission of hepatitis B infection from hepatitis B core antibody-positive liver allografts is prevented by lamivudine therapy. Liver Transplant 2001;7:513-7.
30. Dodson SF, Bonham CA, Geller DA, Cacciarelli TV, Rakela J, Fung JJ. Prevention of de novo hepatitis B infection in recipients of hepatic allografts from anti-HBc positive donors. Transplantation 1999;68: 1058-61.
31. Loss GE, Mason AL, Blazeck J, Dick D, Lipscomb J, Guo L, et al. Transplantation of livers from HBc Ab positive donors into HBc negative recipients: a strategy and preliminary results. Clin Transplant 2001;15(Suppl 6):55-8.
32. Paletta L. Organ procurement issues related to viral hepatitis. In: Lewis D, McCoy J, eds. Donor management notes, vol. 2. Sally A. Todt, 1996: No 5, October, p 1.
33. Pereira B, Levey A. Hepatitis C virus infection in dialysis and renal transplantation. Kidney Int 1997;51:981-99.
34. Fishman J, Rubin R, Koziel M, Periera BJC. Hepatitis C virus and organ transplantation. Transplantation 1996;62:147-54.
35. Diagnostic tests for HIV. Med Lett Drugs Ther 1997;39:81-3.
36. Hinuma Y, Komoda H, Chosa T, Kondo T, Kohakura M, Takenaka T, et al. Antibodies to adult T-cell leukemia-virus-associated antigen (ATLA) in sera from patients with ATL and controls in Japan: a nation-wide sero-epidemiologic study. Int J Cancer 1982;29:631-5.
37. Murphy EL, Figueroa JP, Gibbs W, Holding-Cobham M, Cranston B, Malley K, et al. Human T-lymphotrophic virus type I (HTLV-I) seroprevalence in Jamaica. 1. Demographic determinants. Am J Epidemiol 1991;133:1114-24.
38. Wiktor SZ, Piot P, Mann JM, Nzilambi N, Francis H, Vercauteren G, et al. Human T-cell lymphotrophic virus type I (HTLV-I) among females prostitutes in Kinshasa, Zaire. J Infect Dis 1990;161:1073-7.
39. Fleming AF, Maharajan R, Abraham M, Kulkami AG, Bhusnurmath SR, Okpara RA, et al. Antibodies to HTLV-I in Nigerian blood donors, their relatives and patients with leukaemias, lymphomas, and other diseases. Int J Cancer 1986;38:809-13.
40. Lillo F, Varnier OE, Sabbatani S, Ferro A, Mendez P. Detection of HTLV-I and not HTLV-II infection in Guinea Bissau (West Africa). J Acquir Immun Defic Syndr 1991;4:541-2.
41. Kondo T, Nonaka H, Miyamoto N, Yoshida R, Matsue Y, Ohguchi Y, et al. Incidence of adult T-cell leukemia-lymphoma and its familial clustering. Int J Cancer 1985;35:749-51.
42. Murphy EL, Hanchard B, Figueroa JP, Gibbs WN, Lofters WS, Campbell M, et al. Modelling the risk of adult T-cell leukaemia/lymphoma in persons infected with human T-lymphotropic virus type I. In J Cancer 1989;43:250-3.
43. Kaplan JE, Osame M, Kubota H, Igata A, Nishitani H, Maeda Y, et al. The risk of development of HTLV-I associated myelopathy/tropical spastic paraparesis among persons infected with HTLV-I. J Acquir Immun Defic Syndr 1990;3:1096-101.
44. La Grenade L, Hanchard B, Fletcher V, Cranston B, Blattner W. Infective dermatitis of Jamaican children: a marker for HTLV-I infection. Lancet 1990;336:1345-7.
45. Kalyanaraman VS, Sagadharan MG, Robert-Guroff M, Miyoshi I, Blayney D, Golde D, et al. A new subtype of human T-cell leukemia virus (HTLV-II) associated with a T-cell variant of hairy cell leukemia. Science 1982;218:571-3.
46. Rosenblatt JD, Golde DW, Wachsman W, Giorgi JV, Jacobs A, Schmidt GM, et al. A second isolate of HTLV-II associated with atypical hairy-cell leukaemia. N Engl J Med 1986;315:372-7.
47. Wiktor SZ, Pate EJ, Weiss SH, Gohd RS, Correa P, Fontham ET, et al. Sensitivity of HTLV-I antibody assays for HTLV-II. Lancet 1991;338:512-3.
48. Cossen C, Hagens S, Fukuchi R, Forghani B, Gallo D, Ascher M. Comparison of six commercial human T-cell lymphotropic virus type I (HTLV-I) enzyme immunoassays kits for detection of antibody to HTLV-I and -II. J Clin Microbiol 1992;30:724-5.
49. Claquin J, Romano P, Noury D, Borsarelli J, Jacob F, Feuillerat J-P, et al. Human T lymphotropic virus 1-2 positive antibodies in potential organ donors in France. Transplant Proc 1996;28:189-90.
50. Sullivan MT, Williams AE, Fang CT, Grandinetti T, Poiesz BJ, Ehrlich GD. Transmission of human T-lymphotropic virus types I and II by blood transfusion. Arch Intern Med 1991;151:2043-8.
51. Donegan E. Transfusion Safety Study (TSS) Group. Comparison of HTLV-I/II with HIV-1 transmission by component type and shelf storage before administration [abstract]. Transfusion 1989;29:(38S).
52. Gottesdiener K. Transplanted infections: donor to host transmission with the allograft. Ann Intern Med 1989;110:1001-16.
53. Orr K, Gould F, Short G, Dark JH, Hilton CJ, Corris PA, et al. Outcome of toxoplasma gondii mismatches in heart transplant recipients over a period of 8 years. J Infect 1994;29:249-53.
54. Podzamczer D, Miro J, Bolao F, Gatell JM, Cosin J, Sirera G, et al. Twice-weekly maintenance therapy with sulfadiazine-pyrinethamine to prevent recurrent toxoplasic encephalitis in patients with AIDS. Ann Intern Med 1995;123:175-80.
55. Snydman DR. Organ donor screening for infectious diseases. Transplantation 1998;65:603-10.
56. Quagliarello VJ, Scheld WM. Treatment of bacterial meningitis. N Engl J Med 1997;336:708-16.
57. Décret no 97-928 du 9 Octobre 1997.
58. Articles L. 665-10 et L. 665-15 du Code de la Santé Publique. Deuxième partie: Décrets en Conseil d'Etat.
59. Emre S, Schwartz ME, Altaca G, Sethi P, Fiel MI, Guy SR, et al. Safe use of hepatic allografts from donors older than 70 years. Transplantation 1996;62:62-5.
60. Casavilla A, Mazariegos G, Fung JJ. Cadaveric liver donors: what are the limits? Transplant Proc 1996;28:21-3.
61. Campbell G, Sutherland FR. Non-heart-beating organ donors as a source of kidneys for transplantation: a chart review. CMAJ 1999;160:1573-6.
62. Casavilla A, Ramirez C, Shapiro R, Nghiem D, Miracle K, Bronsther O, et al. Experience with liver and kidney allografts from non-heart-beating donors. Transplantation 1995;59:197-203.
63. Koostra G. The asystolic, or non-heart-beating donor. Transplantation 1997;63:917-21.
64. D'Alessandro AM, Hoffmann RM, Knechtle SJ, Eckhoff DE, Love RB, Kalayoglu M, et al. Successful extra-renal transplantation from non-heart beating donors. Transplantation 1995;59:977-82.
65. Richter S, Yamauchi J, Minor T, Vollmar B, Menger MD. Effect of warm ischemia time and organ perfusion technique on liver microvascular preservation in a non-heart-beating rat model. Transplantation 2000;69:20-4.
66. Harland RC. Selection, management, and organ procurement in the non-heart-beating donor. Curr Opin Organ Transplant 1997;2:164-8.
67. Verran DJ, Gurkan A, Dilworth P, Painter D, Dorney CS, Shun A, et al. Inferior liver allograft survival from cadaveric donors > 50 years of age? Clin Transplant 2001;15:106-10.
68. Cacciarelli TV, Esquivel CO, Moore DH, Cox KL, Berquist WE, Conception W, et al. Factors affecting survival after orthotopic liver transplantation in infants. Transplantation 1997;64:242-8.
69. Horowitz M. Aging and the gastrointestinal tract. Chapter 102. The Merck Manual of Geriatrics, Sec. 13. Gastrointestinal disorders.
70. Adam R, Astarcioglu I, Azoulay D, Morino M, Bao YM, Castaing D, et al. Age greater than 50 years is not a contraindication for liver donation. Transplant Proc 1991;23:2602-3.
71. Jimenez RC, Moreno GE, Colina RF, Palma FC, Loinaz CS, Rodriguez FG, et al. Use of octogenarian livers safely expands the donor pool. Transplantation 1999;68:572-5.
72. Berenguer M, Prieto M, San Juan F, Rayon JM, Martinez F, Carrasco D, et al. Contribution of donor age to the recent decrease in patient survival among HCV-infected liver transplant recipients. Hepatology 2002;36:202-10.
73. Valayer J. Yandza T, Gauthier F, et al. Prélèvement en vue de la transplantation hépatique pédiatrique. In: Nivet H, ed. Les prélèvements d'organes pour la transplantation. Doin, Paris, 1992. pp 287-95.
74. Petz W, Spada M, Sonzogni A, Colledan M, Segalin A, Lucianetti A, et al. Pediatric split liver transplantation using elderly donors. Transplant Proc 2001;33:1361-3.
75. Otte JB, Squiffiet JP, Carlier MC, de Hemptinne B, Gianello P, Dereme T, et al. Organ procurement in children. Surgical, anaesthetic and logistic aspects. Intensive Care Med 1989;15:567-70.
76. Boudjema K, Lindell SL, Southard JH, Belzer FO. The effects of fasting on the quality of liver preservation by simple cold storage. Transplantation 1990;50:943-8.
77. Avolio AW, Agnès S, Chirico AS, Castagneto M. Primary dysfunction after liver transplantation: donor or recipient fault? Transplant Proc 1999;31:434-6.
78. Nery JR, Weppler D, Ketchum P, Olson L, Fragulidis GP, Khan MF, et al. Donor infection and primary nonfunction in liver transplantation. Transplant Proc 1997;29:481-3.
79. Koneru B, Dikdan G. Hepatic steatosis and liver transplantation current clinical and experimental perspectives. Transplantation 2002;73:325-30.
80. Lerut J, de Goyet JV. Technique of multiorgan procurement. Curr Opin Organ Transplant 1997;2:157-63.
81. D'Alessandro AM, Kalayoglu M, Sollinger HW, Hoffmann RM, Reed A, Knechtle SJ, et al. The predictive value of donor liver biopsies for the development of primary nonfunction after orthotopic liver transplantation. Transplantation 1991;51:157-63.
82. Fishbein TM, Fiel MI, Emre S, Cubukcu O, Guy SR, Schwartz ME, et al. Use of livers with microvesicular fat safely expands the donor pool. Transplantation 1997;64:248-51.
83. Zamboni F, Franchello A, David E, Rocca G, Ricchiuti A, Lavezzo B, et al. Effect of macrovesicular steatosis and other donor and recipient characteristics on the outcome of liver transplantation. Clin Transplantation 2001;15:53-7.
84. Miki C, Iriyama K, Mirza DF, Mayer AD, Buckels JA, Suzuki H, et al. Postperfusion energy metabolism of steatotic graft and its relation to early graft viability following liver transplantation. Dig Dis Sci 1998;43:74-9.
85. Chui A, Haghighi K, Painter D, Jayasundera M, Hall G, Rao AR, et al. Donor fatty (steatotic) liver allografts in orthotopic liver transplantation. Transplant Proc 1998;30:3286-7.
86. Strasberg S, Howard T, Molmenti E, Hertl M. Selecting the donor liver: risk factors for poor function after orthotopic liver transplantation. Hepatology 1994;20:829-38.
87. Canelo R, Braun F, Sattler B, Klinge B, Lorf Th, Ramadori G, et al. Is a fatty liver dangerous for transplantation? Transplant Proc 1999;31:414-5.
88. Younossi ZM, Diehl AM, Ong JP. Nonalcoholic fatty liver disease: an agenda for clinical research. Hepatology 2002;35:746-52.
89. Clain DJ, Lefkowitch JH. Fatty liver disease in morbid obesity. Gastroenterol Clin North Am 1987;1987:16:239-52.
90. Angulo P. Nonalcoholic fatty liver disease. N Engl J Med 2002;346:1221-31.
91. Marsman WA, Wiesner RH, Rodriguez L, Batts KP, Porayko MK, Hay JF. Use of fatty donor liver is associated with dimished early patient and graft survival. Transplantation 1996;62:1246.
92. Urena MAG, Ruiz-Delgado FC, Gonzalez EM. Hepatic steatosis in liver transplant donors: common feature of donor population. World J Surg 1998;22:837.
93. Teramoto K, Bowers JL, Khettry U, Palombo JD, Clouse ME. A rat fatty liver transplant model. Transplantation 1993;55:737.
94. Seifalian AM, Chidambaram V, Rolles K, Davidson BR. In vivo demonstration of impaired microcirculation in steatotic human liver grafts. Liver Transplant Surg 1998;4:71.
95. Fukumori T, Ohkohchi N, Tsukamoto S, Satomi S. The mechanism of injury in a steatotic liver graft during cold preservation. Transplantation 1999;67:195-200.
96. Hayashi M, Tokunaga Y, Fujita T, Tanaka K, Yamaoka Y, Ozawa K. The effects of cold preservation on steatotic graft viability in rat liver transplantation. Transplantation 1993;56:282.
97. Hui AM, Kawasaki S, Makuuchi M, Nakayema J, Ikegami T, Miyagawa S, et al. Liver injury following normothermic ischemia in steatotic rat liver. Hepatology 1994;20:1287.
98. Rashid A, Wu TC, Huang CC, Chen CH, Lin HZ, Yang SO. Mitochondrial proteins that regulate apoptosis and necrosis are induced in mouse fatty liver. Hepatology 1999;29:1131.
99. Soltys K, Dikdan G, Koneru B. Evidence of oxidative stress in fatty livers of obese Zucker rats: rapid amelioration and improved tolerance to warm ischemia with tocopherol. Hepatology 2001;34:13.
100. Vendemiale G, Grattagliano I, Caraceni P, Caracciio G, Dominicali M, Dall'Agata M. Mitochondrial oxydative injury and energy metabolism alteration in fatty liver: effect of nutritional status. Hepatology 2001;33:808-15.
101. Serracino-Inglott F, Habib NA, Mathie RT. Hepatic ischemia-reperfusion injury. Am J Surg 2001;181:160-6.
102. Yandza T, Boutron A, Conti M, Fabre M, Lambotte L, Lemonnier A, et al. Production des radicaux libres oxygénés et rôle des antioxydants exogènes en transplantation du foie chez le rat. Chirurgie. 1993-1994;119:109-12.
103. Hayas HI, Tokunaga Y, Fujita T, et al. The effects of cold preservation on steatotic graft viability in rat liver transplantation. Transplantation 1993;56:282.
104. Nakano H, Nagasaki H, Barama A, Boudjema K, Jaeck D, Kumedo K, et al. The effects of N-acetylcysteine and anti-intercellular adhesion molecule-1 monoclonal antibody against ischemia-reperfusion injury of the rat steatotic liver produced by a choline-methionine-deficient diet. Hepatology 1997;26:670-8.
105. Rinella ME, Alonso E, Rao S, Whitington P, Fryer J, Abecassis M, et al. Body mass index as a predictor of hepatic steatosis in living liver donors. Liver Transplant 2001;7:409-14.
106. Angulo P, Keach JC, Batts KP, Lindor KD. Independent predictors of liver fibrosis in patients with nonalcoholic steatohepatitis. Hepatology 1999;30:1356-62.
107. Ratziu V, Giral P, Charlotte F, Brucker E, Thibault V, Theodorou I, et al. Liver fibrosis in overweigth patients. Gastroenterology 2000;118: 1117-23.
108. Adam R, Reynes M, Johann M, Morino M, Astarcioglu I, Kafetzis I, et al. The outcome of steatotic grafts in liver transplantation. Transplant Proc 1991;23:1538-40.
109. Siegelman ES, Rosen MA. Imaging of hepatic steatosis. Semin Liver Dis 2001;1:71.
110. Brokelman W, Stel AL, Ploeg RJ. Risk factors for primary dysfunction after liver transplantation in the University of Wisconsin solution era. Transplant Proc 1999;31:2087-90.
111. Seu P, Imagawa DK, Olthoff KM, Yersiz H, Rosenthal TJ, Abe M, et al. A prospective study on the reliability and cost effectiveness of preoperative ultrasound screening of the «marginal» liver donor. Transplantation 1996;62:129-30.
112. Mor E, Klintmalm GB, Gonwa TA. The use of marginal donors for liver transplantation. A retrospective study of 365 liver donors. Transplantation 1992;53:383-6.
113. Azoulay D, Hargreaves GM, Bismuth H. Impact of liver surgery on liver transplantation. Curr Opin Organ Transplant 2000;5:57-63.
114. Adam R, Castaing D, Bismuth H. Transplantation of small donor livers in adult recipients. Transplant Proc 1993;25:1105-6.
115. Yandza T, Gauthier F, De Dreuzy O, Lababidi A, Dubousset AM, Devictor D, et al. Utilisation des foies réduits en transplantation chez l'enfant. Presse Med 1993;20:940-4.
116. Noujaim HM, Mayer DA, Buckles JAC, Beath SV, Kelly DA, McKieman PJ, et al. Techniques for and outcome of liver transplantation in neonates and infants weighing up to 5 kilograms. J Ped Surg 2002;37:159-64.
117. Herrera LA, Castillo J, Martino E, Rabanal JM, Fleitas MG. Orthotopic liver transplantation from a donor with abdominal situs inversus. Transplantation 1996;62:133-5.
118. Rodriguez-Quiantan FJ, Toledo-Pereira LH. Organ donor criteria and procurement techniques. In: Toledo-Pereira LH. Organ procurement and preservation for transplantation. 2nd ed. Landes Bioscience and Chapman & Hall, 1997, pp 17.
119. Briceno J, Marchal T, Padillo J, Solozarno G, Pera C. Influence of marginal donors on liver preservation injury. Transplantation 2002;74:522-6.
120. Cortiana M, Zagara G, Fava S, Seveso M. Coagulation abnormalities in patients with head injury. J Neurosurg Sci 1986;30:133-8.
121. Masson F, Thicoipe M, Maurette N, Pinaquy C, Léger A, Erny P. Perturbations de l'hémodynamique, de la coagulation et de la glycorégulation induites par la mort cérébrale. Ann Fr Anesth Réanim 1990;9:115-22.
122. Fodgall RP. Coagulation disorders and complications. Sem Anesth 1983;2:143.
123. Bjorklid E, Storm-Mathisen J, Strom E, Prydz H. Localization of tissue thromboplastin in the human brain. Thromb Haemost 1977;37:91.
124. Figueras J, Busquets J, Grande L, Jaurrieta E, Perez-Ferreiroa J, Mir J, et al. The deleterious effect of donor high plasma sodium and extended preservation in liver transplantation. A multivariate analysis. Transplantation 1996;61:410-3.
125. Gonzalez FX, Rimola A, Grande L, Antolin M, Garcia-Valdecasas JC, Fuster J, et al. Predictive factors of early postoperative graft function in human liver transplantation. Hepatology 1994;20:565-73.
126. Briceno J, Pera-Rojas C, Solorzano G, De La Mata M, Pera-Madrazo C. Use of high-risk liver donors for urgent and elective liver transplantation. Transplant Proc 1999;31:440-2.
127. Karayalcin K, Mirza DF, Harrison RF, Da Silva RF, Hubscher SG, Mayer AD, et al. The role of dynamic and morphologic studies in the assessment of potential liver donors. Transplantation 1994;57: 1323-7.
128. Kalayoglu M, Sollinger WH, Stratta RJ, D'Alessandro AM, Hoffmann RM, Pirsch JD, et al. Extended preservation of the liver for clinical transplantation. Lancet 1988;1:617-8.
129. Adam R, Bismuth H, Diamond T, Ducot B, Morino M, Astarcioglu I, et al. Effect of extended cold ischemia with UW solution on graft function after liver transplantation. Lancet 1992;340:1373-6.
130. Fukuhara H, Todo S, Imventarza O, Casavilla A, Wu YM, Scotti-Foglieni C, et al. Effect of cold ischemic time on the early outcome of human hepatic allografts preserved with UW solution. Transplantation 1991;51:1000-4.
131. Hantson Ph, Kremer Y, Lerut J, Squifflet J-P, Mahieu P. Successful liver transplantation with a graft from a methanol-poisoned donor. Transplant Int 1996;9:437.
132. Hantson Ph. The poisoned donors. Curr Opin Organ Transplant 1999;4:125-9.
133. Verran D, Chui A, Painter D, Shun A, Dorney S, McCaughan G, et al. Use of liver allografts from carbone monoxide poisoned cadaveric donors. Transplantation 1996;62:1514-5.
134. Hantson Ph, Squifflet JP, Vanormelingen P, Mahieu P. Organ transplantation after fatal cyanide poisoning. Clin Transplant 1999;13:72-3.
135. Hantson Ph, Vekemans MC, Squifflet JP, Mahieu P. Outcome following organ removal from poisoned donors: experience with 12 cases and review of the literature. Transplant Int 1995;8:185-9.
136. Fattinger KE, Rentsch KM, Meier PJ, Dazzi H, Krähenbühl S. Safety of liver donation after fatal intoxication with the tricyclic antidepressant trimipramine. Transplantation 1996;62:1259-62.
137. Yandza T, Goulao J, Gauthier F, Devictor D, De Dreuzy O, Huault G, et al. The use in pediatric liver transplantation of livers from donors who died from anoxia. Transplant Proc 1991;23:2617.
138. Marsh JW, Esquivel CO, Makowka L, et al. Accidental transplantation of malignant tumor from a donor to multiple recipients. Transplantation 1987;44:449.
139. Doutrelepont JM, Mat O, Abramowicz D, Piccart M, Kercer J, De Pauw L, et al. Inadvertent transfer of choriocarcinoma with renal transplantation: characteristics of the donor-recipient pairs. Transplant Proc 1995;27:1789-90.
140. Centers for Disease Control. Update: Creutzfeldt-Jacob disease in a patient receiving a cadaveric dura mater graft. JAMA 1987;258:309-10.
141. Circulaire Direction Générale de la Santé/DH/94 No 5 du 12/01/95.
142. Cecka JM, Teresaki PI. The UNOS Scientific Renal Transplant Registry-1991. In: Terasaki PI., ed Clinical Transplants 1991. Los Angeles: UCLA Tissue Typing Laboratory, pp 1.
143. Azoulay D, Samuel D, Castaing D, Adam R, Adam D, Said G, et al. Domino liver transplants for metabolic disorders: experience with familial amyloidotic polyneuropathy. J Am Coll Surg 1999;189:584-93.
144. Azoulay D, Castaing D, Adam R. Transplantation of three adult patients with one cadaveric graft: wait or innovate? Liver Transplant 2000;6:239-40.
145. Furtado AJL. Domino liver transplantation using livers from patients with familial amyloidotic polyneuropathy. Curr Opin Organ Transplant 2000;5:69-73.
146. Tantawi B, Cherqui D, Duvoux C, Dhumeaux D, Fagniez PL. Reuse of a liver graft five days after initial transplantation. Transplantation 1996;62:868-9.
147. Moreno EG, Garcia GI, Gonzalez-Pinto I, Gomez SR, Loinaz SC. Successful reuse of a liver graft. Br J Surg 1991;78:813-4.
148. Lowell JA, Taranto SE, Singer GG, Miller SB, Ghalib R, Caldwell C, et al. Transplant recipients as organ donors: the domino transplant. Transplant Proc 1997;29:3392-3.
149. Gugheneim J, Samuel D, Reynes M, Bismuth H. Liver transplantation across ABO blood group barriers. Lancet 1990;336:519-23.
150. Yandza T, Lambert T, Bernard O, Alvarez F, Gauthier F, Jacolot D, et al. The outcome of ABO incompatible liver transplantation in children with no specific alloantibodies at the time of transplantation. Transplantation, 1994;58:46-50.
151. Fishbein TM, Emre S, Guy SR, Sheiner PA, Kim LH, Schwartz ME, et al. Safe transplantation of blood type A2 livers to blood type O recipients. Transplantation 1999;67:1071-3.
152. Claquin J. Bilan d'activité. Premier semestre 2002. Service de Régulation et d'Appui Ile-de-France/Centre/Les Antilles. Etablissement Français des Greffes.